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AbstrACt
Introduction Surgery (oesophagectomy), with 
neoadjuvant chemo(radio)therapy, is the main curative 
treatment for patients with oesophageal cancer. 
Several surgical approaches can be used to remove an 
oesophageal tumour. The Ivor Lewis (two- phase procedure) 
is usually used in the UK. This can be performed as an 
open oesophagectomy (OO), a laparoscopically assisted 
oesophagectomy (LAO) or a totally minimally invasive 
oesophagectomy (TMIO). All three are performed in the 
National Health Service, with LAO and OO the most 
common. However, there is limited evidence about which 
surgical approach is best for patients in terms of survival 
and postoperative health- related quality of life.
Methods and analysis We will undertake a UK 
multicentre randomised controlled trial to compare 
LAO with OO in adult patients with oesophageal cancer. 
The primary outcome is patient- reported physical 
function at 3 and 6 weeks postoperatively and 3 months 
after randomisation. Secondary outcomes include: 
postoperative complications, survival, disease recurrence, 
other measures of quality of life, spirometry, success 
of patient blinding and quality assurance measures. A 
cost- effectiveness analysis will be performed comparing 
LAO with OO. We will embed a randomised substudy to 
evaluate the safety and evolution of the TMIO procedure 
and a qualitative recruitment intervention to optimise 
patient recruitment. We will analyse the primary outcome 
strengths and limitations of this study
 ► The Randomised Oesophagectomy: Minimally 
Invasive or Open (ROMIO) study will compare lap-
aroscopically assisted oesophagectomy with open 
oesophagectomy, which are the procedures most 
relevant to UK practice.
 ► We will assess the quality of the surgery, using oper-
ative images and pathology.
 ► The primary outcome (recovery of physical function 
up to 3 months) considers what matters most to pa-
tients about having an oesophagectomy.
 ► Patients will be blinded to their surgical procedure 
for 6 days postoperatively (using large dressings) 
to achieve an unbiased assessment of pain, but it 
will not be possible to blind patients for the primary 
outcome.
 ► ROMIO incorporates a randomised substudy to col-
lect data on totally minimally invasive oesophagec-
tomy, which is an evolving technique.
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using a multi- level regression model. Patients will be monitored for up to 3 
years after their surgery.
Ethics and dissemination This study received ethical approval from 
the South- West Franchay Research Ethics Committee. We will submit the 
results for publication in a peer- reviewed journal.
trial registration number ISRCTN10386621.
IntroduCtIon
In the UK, about 8900 people are diagnosed with oesoph-
ageal cancer each year and the incidence is increasing.1 
Surgical removal of the oesophagus (oesophagectomy), 
with or without chemo(radio)therapy, is currently the 
most commonly recommended treatment for patients 
whose cancer is confined to the oesophagus and the 
local lymph nodes and who are fit to undergo major 
surgery. The objective of treatment is a surgical cure 
but only about 40%–50% of patients survive for 3 years 
or more following treatment.1 The surgical procedure 
depends on the location and size of the tumour and indi-
vidual surgeon choice. There are a number of different 
surgical approaches used in the National Health Service 
(NHS), but the most commonly used procedure involves 
removing the bottom part of the oesophagus and part 
of the top of the stomach (the two- phase Ivor Lewis 
oesophagectomy). The remaining stomach is fashioned 
into a tube and brought up into the chest to replace the 
removed oesophagus.
In the past 10 years, there has been an increase in 
the use of minimally invasive surgical techniques and, 
according to the latest Association of Upper Gastro- 
Intestinal Surgeons audit, 42% of oesophagectomies were 
performed using laparoscopically assisted oesophagec-
tomy (LAO) or totally minimally invasive oesophagectomy 
(TMIO).2 However, it is uncertain whether laparoscopic 
surgery improves patient recovery after surgery or has any 
impact on survival.
Observational studies suggest that TMIO achieves the 
same survival benefit as open oesophagectomy (OO), but 
with better recovery and reduced rates of postoperative 
pneumonia,3–5 although the apparent faster recovery 
may be due to the selection of fitter patients for the mini-
mally invasive procedure. To date, seven randomised 
controlled trials (RCTs) comparing OO with LAO (n=2), 
or TMIO (n=4), or robot- assisted TMIO (n=1) have been 
conducted.6–12 All had modest sample sizes (26–221 
patients) and five out of the seven studies were conducted 
in a single centre (China=3, Austria=1, The Nether-
lands=1). The studies measured short- term primary 
outcomes such as pulmonary infection (n=2),7 9 postop-
erative complications (n=4)6 10–12 and duration of opera-
tion (n=1).8 In one RCT, patients were randomised to a 
surgeon rather than procedure, meaning the treatment 
effect may be influenced by a difference in skill between 
surgeons choosing LAO and those choosing OO.11 All but 
one of the RCTs12 were at unclear risk of selection bias, 
either due to random sequence generation (n=3) or allo-
cation concealment (n=6). The best evidence comes from 
two multicentre RCTs, MIRO (hybrid minimally invasive 
versus open oesophagectomy for patients with oesopha-
geal cancer) and TIME (traditional invasive vs minimally 
invasive oesophagectomy). MIRO randomised 207 partic-
ipants in 12 French centres. Patients were randomised to 
OO (n=104) or LAO (n=103). They compared intraoper-
ative and postoperative complications, classified as grade 
2 or above using Clavien- Dindo, within 30 days. There was 
a lower incidence of complications in those allocated to 
LAO (36%) compared with those allocated to OO (64%, 
OR 0.31, 95% CI 0.18 to 0.55) However, patients were 
randomised using opaque envelopes in theatre after a 
preoperative laparoscopic investigation.10 The TIME trial, 
conducted in five European centres, compared TMIO 
with OO in 115 patients7 and reported a 70% reduction 
in pulmonary infection in the TMIO group in the first 
2 weeks postoperatively (relative risk (RR) 0.30, 95% CI 
0.12 to 0.76).7 However, the TMIO procedure is not well- 
established in the UK.13
We are conducting a large, multicentre RCT (the 
ROMIO trial) to compare the clinical and cost- 
effectiveness of LAO versus OO. The trial will provide 
high- quality evidence, relevant to UK practice, of the risks 
and benefits of LAO, in terms of recovery, health- related 
quality of life (HRQoL), cost and survival. Incorporated 
into the study are:
 ► An assessment of the quality of the surgery performed, 
using intraoperative photos of the procedure and 
pathology reports.14
 ► An integrated qualitative QuinteT Recruitment Inter-
vention to optimise recruitment.15
 ► A nested randomised substudy (designed as a phase 
2b study within the innovation,development, explora-
tion, assessment, and long- term study, IDEAL, frame-
work) to investigate the safety and technical changes 
in TMIO.16
MEthods And AnAlysIs
We have used the Standard Protocol Items: Recommen-
dations for Interventional Trials reporting guidelines in 
this protocol paper.17
study design
ROMIO is a multicentre RCT comparing OO with LAO 
in patients with oesophageal cancer. ROMIO will also 
include a nested randomised substudy in two centres 
to assess the efficacy of TMIO and review safety data, 
compared with OO and LAO. The substudy will also 
document how the technical aspects of TMIO evolve 
over time and whether the technique ‘stabilises’ over the 
course of ROMIO.
Entry criteria
To ensure comparability between centres and surgeons, 
centres will only be included if they are undertaking at 
least 50 oesophagectomies per year and have a minimum 
of two surgeons participating in ROMIO. Surgeons will 
be assessed (by electronically submitting two unedited 
anonymised videos to the ROMIO study imaging team) 
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Figure 1 Consort diagram outline. MDT, multidisciplinary team; PIL, patient information leaflet; TMIO, totally minimally invasive 
oesophagectomy; LAO, laparoscopically assisted oesophagectomy; OO, open oesophagectomy.
before they will be permitted to enrol their patients for 
ROMIO. Further details about this quality assurance 
(QA) measure has been described previously.14
Inclusion criteria
We will screen all patients undergoing oesophagectomy 
(with or without neoadjuvant chemo(radio)therapy) in 
at least eight UK hospitals for eligibility (figure 1). We 
will include patients who are at least 18 years of age, with 
at least adenocarcinoma or squamous cell cancer of the 
oesophagus or oesophago- gastric junction, who have been 
referred for oesophagectomy by the multidisciplinary 
team after neoadjuvant chemotherapy or chemo(radio)
therapy (any type). Patients will be included if their 
tumour is localised (has not spread beyond the local 
lymph nodes), is >5 cm below the cricopharyngeus (the 
muscle that keeps the oesophagus shut) and involves 
<4 cm of the stomach wall. Patients will only be included 
if they have been assessed as fit for surgery and are able to 
provide written informed consent.
Exclusion criteria
Patients will be excluded if they have high- grade dysplasia 
or if the cancer has spread beyond the oesophagus (T4b) 
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Figure 2 Diagrams representing the incisions the surgeon 
may make for the three different surgical approaches.
or any stage with M1. All patients must be eligible for 
either open or minimally invasive surgery and must not 
be taking part in any other research that would interfere 
with the ROMIO protocol.
Randomisation
The local research team will take written informed 
consent from participants. They will then randomise 
participants up to 2 weeks before their operation using a 
secure internet- based randomisation system. A computer 
programme will be used to generate the allocation 
sequence used for randomisation. Randomisation will be 
stratified by neoadjuvant treatment and site. Randomisa-
tion within blocks of varying size will prevent large imbal-
ances in the number of patients in each treatment group. 
Participants will be randomised to receive either OO or 
LAO in a 1:1 ratio (with a varying block size of 6 or 8). In 
two centres, patients may also be randomised to receive 
TMIO, in a 1:1:1 ratio (with a varying block size of 6 or 
9). The surgical team will be informed of the patient allo-
cation after randomisation and before surgery (figure 1).
Trial interventions
The intervention being compared in ROMIO is the 
surgical approach, that is, whether the surgeon uses large 
(OO) or smaller incisions (LAO or TMIO) to perform 
the operation (figure 2). Internally, the operation being 
performed is expected to be the same, regardless of the 
surgical approach used. Placement of a feeding jejunos-
tomy or naso- jejunal tube will also at the surgeon’s discre-
tion, as well as the use of intra- abdominal and intrathoracic 
drains. Details of the surgical technique were established 
during the feasibility study and as part of the embedded 
QA study and are intended to be pragmatic.14 18 OO will 
be performed using large incisions in both the abdomen 
and the chest (figure 2); the location and length of 
incisions are at each surgeon’s discretion. LAO will be 
performed laparoscopically using 5 and/or 12 mm inci-
sions (as many as needed, according to surgeon’s prefer-
ence) in the abdomen. One large incision will be made 
in the chest (figure 2). If a feeding jejunostomy tube is 
placed, this may be performed laparoscopically or by 
creating an abdominal incision (no bigger than 8 cm). 
In the two centres participating in the substudy, around 
33% of patients will have a TMIO. In this approach, the 
surgeon will make small incisions in the abdomen and 
in the chest. For the abdominal part of the procedure, 
laparoscopic techniques will be used as described above. 
The surgeon will access the thoracic cavity using 12 and/
or 5 mm incisions (as many as needed) and perform the 
surgery thoracoscopically (figure 2).
Procedures to minimise diaphragmatic herniation 
(where one or more of the abdominal organs moves into 
the chest) can be performed at the surgeon’s discretion. 
The anastomotic technique and methods to close the 
incisions are at the surgeon’s discretion. Any deviations 
from the specified procedures must be fully documented 
and will be reviewed by the study management group.
All surgical interventions will be carried out under 
general anaesthesia according to local hospital protocols. 
Patients will receive antibiotics and deep vein thrombosis 
prophylaxis according to local hospital policies. Co- in-
terventions such as perioperative analgesia (eg, epidural 
anaesthesia or paravertebral catheters) and monitoring 
(eg, central or arterial lines) will be permitted according 
to the preferences of each centre.
Participants have the right to discontinue their part in 
the study at any time. In addition, the investigator may 
withdraw the participant from their allocated treatment 
group if, subsequent to randomisation, a clinical reason 
for not performing the surgical intervention is discov-
ered. Participants withdrawn from their allocated inter-
vention but willing to continue completing follow- up 
schedules will be encouraged to do so. All discontinua-
tions and withdrawals will be documented.
Primary outcome
The primary outcome is recovery of physical function 
assessed using the established, validated patient- reported 
European Organisation for Research and Treatment of 
Protected by copyright.
 o
n
 N
ovem
ber 26, 2019 at University of Bristol Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030907 on 19 November 2019. Downloaded from 
5Brierley RC, et al. BMJ Open 2019;9:e030907. doi:10.1136/bmjopen-2019-030907
Open access
Cancer quality of life questionnaire (EORTC- QLQ- C30) 
at 3 and 6 weeks postsurgery and 3 months after rando-
misation.19 This quality of life measure was selected as 
the key benefits of minimally invasive surgical techniques 
are the potential for less tissue damage and consequently 
less pain and a more rapid recovery of function.20 Patient 
groups also indicated that quality of life is an outcome 
that is very important to them.
Secondary outcome measures
Secondary outcomes will assess the efficacy of the OO and 
LAO in terms of morbidity, survival and safety. Secondary 
outcomes will include:
Survival
 ► Overall and disease- free survival for at least 2 years.
Complications
 ► All- cause short- term and long- term complications for 
up to 3 years after randomisation.21
 ► Any complications within 30 days of surgery, as 
assessed using the Clavien- Dindo System.22
 ► Length of hospital stay (defined as length of primary 
hospital stay plus readmission within 30 days/length 
of primary hospital stay plus length of hospital stay if 
discharged to community hospital).
 ► Forced expiratory volume in 1 s and forced vital 
capacity measured by spirometry, at baseline and days 
3 and 6 postoperatively.
Cost-effectiveness
 ► Incremental net monetary benefit of LAO over OO 2 
years after surgery.
Quality of life
 ► We will measure generic and disease- specific aspects of 
HRQoL using the following validated questionnaires 
at baseline, 6 days, 3 weeks and 6 weeks postsurgery 
and 3, 6, 9, 12, 18, 24 and (where possible) 36 months 
after randomisation:
 – EORTC QLQ- C3019—a questionnaire developed to 
assess the HRQoL of patients with cancer.
 – EORTC QLQ- OES1823 24—a questionnaire devel-
oped to assess the HRQoL for patients with oesoph-
ageal cancer.
 – Multidimensional fatigue inventory (MFI)-2025 26—
a tool widely used to assess fatigue in patients with 
cancer.
 – EuroQOL EQ- 5D- 5L27 28—a widely used generic 
quality of life questionnaire.
We will also measure pain preoperatively and 
postoperatively at days 3 and 6 using the visual 
analogue scale (VAS).29
Quality assurance
We will assess QA of surgery (reported previously14) using 
the following:
 ► Intraoperative photographs will be taken at key stages 
throughout each procedure and submitted to the 
study database for ongoing monitoring of the opera-
tions. Anonymised images will be reviewed and rated 
by surgical assessors.
 ► Histopathological measures assessed by patholo-
gists blinded to the treatment allocation, including 
length of the oesophagus; total counts of nodes—all 
and malignant (positive) nodes; details of resection 
margins and pT staging. The slides of 10% of all 
cases from each centre will be reviewed by the lead 
pathologist.
 ► Success of patient blinding during the first 6 days post-
operatively, assessed using the Bang Blinding Index.30
Outcome data will be collected onto case report forms 
(unless questionnaires are specified) and entered onto a 
study- specific database for data cleaning and analysis.
Data about adverse events will be collected and reported 
in accordance with sponsor and regulatory requirements.
Patient and public involvement
Patient groups were consulted at the design stage, the 
feedback from these patient consultations shaped the 
primary outcome and other aspects of the study. We 
have patient representatives as grant co- applicants and 
as independent members of the trial steering committee; 
in addition to this, we will regularly consult patient and 
public groups about different aspects of the study as it is 
ongoing. Patients have provided feedback on the burden 
involved in participating in the research.
Methods used to minimise bias
Patients will be blinded to their treatment alloca-
tion by covering all potential incision sites for all 
surgical approaches (regardless of the actual operation 
performed) with large dressings for the first 6 days post-
operatively. On day 6, patients will be asked to complete a 
booklet containing all of the quality of life questionnaires 
(QLQ- C30, OES-18, MFI-20, EQ- 5D- 5L) and a pain assess-
ment using the VAS. Success of blinding will be assessed 
using the Bang Blinding Index.30 Due to the nature of 
the study intervention, it is not possible to blind patients 
for the completion of the quality of life questionnaires at 
the primary outcome timepoints. However, patients have 
not had this surgery before so will not have anything to 
compare it to; furthermore, participants in the study are 
unlikely to have a strong preference for one approach 
over another.
Pathologists assessing QA of surgery will also be blinded 
to the randomised allocation. As the intervention is 
surgery, there may be variation in surgeon skill or surgical 
technique. This will be managed by stratifying the rando-
misation by centre. Surgical QA is described in more 
detail elsewhere.14
Loss to follow- up will be minimised by maintaining 
regular contact with patients (by telephone and post) to 
complete follow- up questionnaires. No additional visits 
are required for the study.
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Sample size
Two hundred three participants in each of the LAO and 
OO groups will allow a minimum clinically important 
difference of 0.4 SD on the primary outcome to be 
detected with >90% power at the 5% significance level, 
allowing for 15% of participants not following their 
allocated procedure, and 10% failing to complete the 
primary outcome. We anticipate that approximately 40 
additional patients will be randomised to TMIO in the 
nested IDEAL phase IIb substudy to allow us to describe 
and evaluate changes in technique.
Statistical analysis
The results will be reported according to the Consoli-
dated Standards of Reporting Trials guidelines, including 
the extension for patient- reported outcomes.31 We will 
analyse the data according to the intention- to- treat prin-
ciple, in that the groups compared will be based on 
allocated treatment irrespective of the actual operation 
that the patient had. Participants missing all three assess-
ments contributing to the primary outcome measure will 
not be included in the primary analysis, but we will use 
sensitivity analyses to investigate the potential impact of 
any missing data. We will adjust analyses for treatment 
centre, whether the participant underwent neoadju-
vant chemo(radio)therapy and the baseline value of the 
outcome under comparison. We will prepare and make 
publicly available a detailed analysis plan prior to locking 
the database.
The primary outcome measure (difference between 
LAO and OO treatment groups) will be the reported 
difference in mean EORTC- QLQ- C30 scores for recovery 
of physical function (with 95% CI and p value). The 
difference in mean scores will be estimated as the coeffi-
cient of a binary variable distinguishing the two treatment 
groups, in a multilevel regression model, with covariates 
as detailed. This analysis will be conducted separately for 
data from the feasibility and main trials, and the two treat-
ment effect estimates pooled as a weighted average. The 
same approach will be adapted to the assessment of pain 
during the 6 days postoperatively and other measures of 
HRQoL.
In addition, we will compare postoperative length of 
stay and accommodate the skewed distribution of this 
measure by a log- transformed analysis model presenting 
ratios of geometric means, 95% CI and p value.
We will present frequencies of the key treatment 
complications by treatment allocation. Severity of treat-
ment complications will be compared between allocated 
treatment groups by scoring each patient according 
to their most severe Clavien- Dindo category and esti-
mating the difference as an OR using ordered logistic 
regression.
We will use proportional hazards regression to esti-
mate the treatment difference in overall and disease- free 
survival. A Kaplan- Meier plot will present survival over 
time in the OO and LAO groups.
Subgroup analyses
A subgroup analysis will investigate whether the rela-
tive effects of OO and LAO differ according to whether 
a participant underwent neoadjuvant chemotherapy/
chemo(radio)therapy beforehand.
Analysis of the nested IDEAL phase IIB substudy
Data about the TMIO group will be collected and 
reported separately to the comparison between the OO 
and LAO groups, these patients will not be included in 
the main analysis. We will document the inclusion/exclu-
sion of patients for the TMIO procedure and any reasons 
for not performing the TMIO operation according to the 
randomised allocation. We will document the complica-
tions of TMIO and perform some analyses of safety and 
adverse events compared with the OO and LAO groups. 
We will document the evolution of the technical aspects 
of this procedure according to the IDEAL phase IIb 
framework.
Cost-effectiveness analysis
We will convert EQ- 5D- 5L18 19 responses to utilities using 
the National Institute for Health and Care Excellence- 
recommended UK tariff at the time of analysis.32 These 
will be combined with survival data to calculate quality- 
adjusted life years, adjusted for differences in baseline 
EQ- 5D utility scores.33 We will estimate theatre costs by 
collecting detailed information on equipment used and 
staff time (eg, surgeons, anaesthetist, scrub nurse). We 
will collect information on intensive care resource use 
and re- interventions during the initial hospital stay. We 
will also collect and analyse data on healthcare resources 
used in subsequent inpatient stays, outpatient visits, 
general practitioner visits and other community health 
services. We will use nationally available unit costs to value 
resource use where available.
We will perform the cost- effectiveness analysis on an 
intention- to- treat basis from both an NHS perspective, 
and a wider personal and social care perspective. We will 
estimate the cost- effectiveness of LAO compared with OO 
by calculating the incremental net monetary benefit and, 
if appropriate, the incremental cost- effectiveness ratio. 
We will present uncertainty in these estimates using a cost- 
effectiveness acceptability curve and/or cost- effectiveness 
ellipses. We will perform cost analyses at 3 and 24 months 
after randomisation. At 24 months, we will discount the 
cost estimates at the rate recommended by HM Treasury 
at the time of analysis.34 We will conduct one- way sensi-
tivity analyses including varying the discount rate. Where 
appropriate, we will use simple or multiple imputation 
techniques for missing data.
EthICs And dIssEMInAtIon
All study interventions are already routinely used in the 
NHS. We will disseminate the findings by usual academic 
channels, that is, presentation at international meet-
ings and peer- reviewed publications. We will write a full 
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report for the funder on the completion of the study and 
we will provide a lay summary of the results to patient 
organisations.
study progress
Recruitment started in October 2016 and we have 
recruited 277 patients, with an additional 32 TMIO 
patients (correct on 3 April 2019). We have agreed with 
the funder to continue recruitment until September 
2019, beyond the planned completion of recruitment in 
November 2018. We will also include approximately 120 
patients recruited to the feasibility study, having secured 
permission to continue recruitment to that study whilst 
the main trial was being set up.
Major changes to the study protocol
Since the first study protocol was approved by the 
Research Ethics Committee (the current version is V.7.0, 
25 October 2018), we have made the following changes:
 ► We updated the expected adverse events section 
to reflect the results of an international consensus 
paper on standardising reporting of complications 
of oesophagectomy21 and to clarify that we will not 
collect events related to chemotherapy.
 ► We included information about plans to link with 
external registries (Intensive Care National Audit 
Research Centre, Public Health England, Information 
Services Division) to obtain more detailed data about 
ROMIO patient care in hospitals, for the purpose 
of economic analysis and to capture information on 
acute postoperative complications and recovery.
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